Item Type | Name |
Concept
|
Carcinoma, Papillary
|
Concept
|
Carcinoma, Squamous Cell
|
Concept
|
Carcinoma
|
Concept
|
Carcinoma, Renal Cell
|
Concept
|
Carcinoma, Non-Small-Cell Lung
|
Concept
|
Carcinoma, Neuroendocrine
|
Concept
|
Carcinoma, Large Cell
|
Concept
|
Carcinoma, Adenoid Cystic
|
Academic Article
|
Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study.
|
Academic Article
|
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
|
Academic Article
|
A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.
|
Academic Article
|
Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase.
|
Academic Article
|
Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer.
|
Academic Article
|
Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma.
|
Academic Article
|
A phase II study of ABT-751 in patients with advanced non-small cell lung cancer.
|
Academic Article
|
A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer.
|
Academic Article
|
Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment.
|
Academic Article
|
The expanding role of systemic therapy in head and neck cancer.
|
Academic Article
|
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
|
Academic Article
|
A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle.
|
Academic Article
|
Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR.
|
Academic Article
|
High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial.
|
Academic Article
|
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
|
Academic Article
|
Personalizing cancer care: updates on head and neck cancer.
|
Academic Article
|
Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas.
|
Academic Article
|
[18F]Fluorodeoxyglucose positron emission tomography in the initial staging of squamous cell carcinoma of the head and neck: promise, evidence, and reality.
|
Academic Article
|
A phase I study of sirolimus and bevacizumab in patients with advanced malignancies.
|
Academic Article
|
A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers.
|
Academic Article
|
Airway management before chemoradiation for advanced head and neck cancer.
|
Academic Article
|
Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck.
|
Academic Article
|
Phase II study of sunitinib malate in head and neck squamous cell carcinoma.
|
Academic Article
|
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
|
Academic Article
|
Planned post-chemoradiation neck dissection: significance of radiation dose.
|
Academic Article
|
Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas.
|
Academic Article
|
A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck.
|
Academic Article
|
Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context.
|
Academic Article
|
Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial.
|
Academic Article
|
Single sample expression-anchored mechanisms predict survival in head and neck cancer.
|
Academic Article
|
Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck.
|
Academic Article
|
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
|
Academic Article
|
Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck.
|
Academic Article
|
Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
|
Academic Article
|
Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.
|
Academic Article
|
Role of molecular markers in the management of head and neck cancers.
|
Academic Article
|
Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin.
|
Academic Article
|
Searching for a standard.
|
Academic Article
|
Locally advanced non-small cell lung cancer.
|
Academic Article
|
Induction chemotherapy and radiotherapy in locally advanced non-small cell lung cancer.
|
Academic Article
|
Esophageal cancer therapy: a decade of inertia.
|
Academic Article
|
Quality of life scores as prognostic factors of overall survival in advanced head and neck cancer: analysis of a phase III randomized trial of pemetrexed plus cisplatin versus cisplatin monotherapy.
|
Academic Article
|
A disturbance in the force--mitochondrial mutations in squamous cell carcinoma of the head and neck.
|
Academic Article
|
Cabozantinib for the treatment of advanced medullary thyroid cancer.
|
Academic Article
|
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
|
Academic Article
|
Current treatment options for metastatic head and neck cancer.
|
Academic Article
|
Novel therapeutic targets in squamous cell carcinoma of the head and neck.
|
Academic Article
|
State-of-the-art management of locally advanced head and neck cancer.
|
Academic Article
|
Mechanisms of resistance to EGFR inhibitors in head and neck cancer.
|
Academic Article
|
Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma.
|
Academic Article
|
A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation.
|
Academic Article
|
Pharmacoeconomic issues in head and neck oncology.
|
Academic Article
|
Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors.
|
Academic Article
|
Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib.
|
Academic Article
|
Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition.
|
Academic Article
|
Novel targeted therapies in head and neck cancer.
|
Academic Article
|
The role of chemotherapy in locally advanced head and neck squamous cell carcinoma.
|
Academic Article
|
The future of induction chemotherapy for head and neck squamous cell carcinoma.
|
Academic Article
|
Epidermal growth factor receptor directed therapy in head and neck cancer.
|
Academic Article
|
Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
|
Academic Article
|
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].
|
Academic Article
|
Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.
|
Academic Article
|
Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma.
|
Academic Article
|
Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy.
|
Academic Article
|
Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes.
|
Academic Article
|
Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades.
|
Academic Article
|
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
|
Academic Article
|
Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss.
|
Academic Article
|
Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements.
|
Academic Article
|
Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck.
|
Academic Article
|
Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy.
|
Academic Article
|
Combined TP53 mutation/3p loss correlates with decreased radiosensitivity and increased matrix-metalloproteinase activity in head and neck carcinoma.
|
Academic Article
|
Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
|
Academic Article
|
Study of functional infrared imaging for early detection of mucositis in locally advanced head and neck cancer treated with chemoradiotherapy.
|
Academic Article
|
Cabozantinib in progressive medullary thyroid cancer.
|
Academic Article
|
Reply to s. Chakraborty et al.
|
Academic Article
|
Mechanisms of and therapeutic approaches for overcoming resistance to epidermal growth factor receptor (EGFR)-targeted therapy in squamous cell carcinoma of the head and neck (SCCHN).
|
Academic Article
|
Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab.
|
Academic Article
|
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
|
Academic Article
|
An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck.
|
Academic Article
|
p62/SQSTM1 accumulation in squamous cell carcinoma of head and neck predicts sensitivity to phosphatidylinositol 3-kinase pathway inhibitors.
|
Academic Article
|
A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck.
|
Academic Article
|
Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments.
|
Academic Article
|
Eruptive cutaneous squamous cell carcinoma and psoriasis: response to cetuximab.
|
Academic Article
|
Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy.
|
Academic Article
|
Integrated genomic analysis suggests MLL3 is a novel candidate susceptibility gene for familial nasopharyngeal carcinoma.
|
Academic Article
|
Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
|
Academic Article
|
Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo.
|
Academic Article
|
Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma.
|
Academic Article
|
Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.
|
Academic Article
|
Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer.
|
Academic Article
|
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial.
|
Academic Article
|
Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.
|
Academic Article
|
Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
|
Academic Article
|
A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC).
|
Academic Article
|
Phase II trial of sunitinib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).
|
Academic Article
|
Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO Evidence-Based Clinical Practice Guideline.
|
Academic Article
|
Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine.
|
Academic Article
|
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
|
Academic Article
|
Evidence-based clinical practice guideline for the evaluation of potentially malignant disorders in the oral cavity: A report of the American Dental Association.
|
Academic Article
|
Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions.
|
Academic Article
|
Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
|
Academic Article
|
Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience.
|
Academic Article
|
Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer.
|
Academic Article
|
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.
|
Academic Article
|
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
|
Academic Article
|
Adjuncts for the evaluation of potentially malignant disorders in the oral cavity: Diagnostic test accuracy systematic review and meta-analysis-a report of the American Dental Association.
|
Academic Article
|
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.
|
Academic Article
|
Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics.
|
Academic Article
|
Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial.
|
Academic Article
|
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
|
Academic Article
|
Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial.
|
Academic Article
|
Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial.
|
Academic Article
|
Selection of Head and Neck Cancer Patients for Intensive Therapy.
|
Academic Article
|
HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.
|
Academic Article
|
SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
|
Academic Article
|
Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States.
|
Academic Article
|
Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial.
|
Academic Article
|
B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade.
|
Academic Article
|
Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040.
|
Academic Article
|
Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study.
|
Academic Article
|
Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study.
|
Academic Article
|
Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer.
|
Academic Article
|
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group.
|
Academic Article
|
Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.
|
Academic Article
|
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.
|
Academic Article
|
Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study.
|
Academic Article
|
Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial.
|
Academic Article
|
Hereditary oral squamous cell carcinoma associated with CDKN2A germline mutation: a case report.
|
Academic Article
|
Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design.
|
Academic Article
|
Role of Induction Chemotherapy Prior to Chemoradiation in Head and Neck Squamous Cell Cancer-Systematic Review and Meta-analysis.
|
Academic Article
|
Somatic 9p24.1 alterations in HPV- head and neck squamous cancer dictate immune microenvironment and anti-PD-1 checkpoint inhibitor activity.
|
Academic Article
|
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
|
Academic Article
|
A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck.
|
Academic Article
|
A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma.
|
Academic Article
|
Programmed death 1 (PD-1) and ligand (PD-L1) inhibitors in head and neck squamous cell carcinoma: A meta-analysis.
|
Grant
|
Maximizing Efficacy of EGFR Inhibitors by Defining Resistance Mechanisms
|
Academic Article
|
Evolving treatment paradigms in recurrent and metastatic head and neck squamous cell carcinoma: the emergence of immunotherapy.
|
Academic Article
|
Method for estimation of apoptotic cell fraction of cytotherapy using in vivo fluorine-19 magnetic resonance: pilot study in a patient with head and neck carcinoma receiving tumor-infiltrating lymphocytes labeled with perfluorocarbon nanoemulsion.
|
Academic Article
|
Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma.
|
Academic Article
|
Facts and Hopes in Neoadjuvant Immunotherapy: Current Approvals and Emerging Evidence.
|
Academic Article
|
Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial.
|
Academic Article
|
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients.
|